TEVA - Should You Buy This Biotech That Makes A Lower Risk Painkiller?
Investing in opioid manufacturers is an endeavor few investors wish to partake in. Between 2011 and 2017, more than 40,000 Americans died each year due to opioid overdose, which has become a full-blown public health crisis. Over 2,500 lawsuits across all 50 states have been brought against manufacturers for drastically understating the risks of addiction associated with their painkiller products in their marketing efforts, with potentially hundreds of billions of dollars at play in the event of settlements.
Meanwhile, approximately 50 million Americans experience chronic pain each year and may require prescription opioids. Currently, there are simply no other options available for fast and effective pain relief for the condition. One company, however, has developed an abuse-deterrent opioid that is rapidly replacing prescriptions of traditional oxycodone. For risk-savvy biotech investors, investing in Collegium Pharmaceutical (NASDAQ: COLL) may present the next brave venture.
IMAGE SOURCE: GETTY IMAGES